| Literature DB >> 33840957 |
R Venkatnarayanan1, Pavitra Manu Dogra2, Rohit Bavdekar3, Sanjeev Kumar Singh1, Asish Kumar Mondal3.
Abstract
INTRODUCTION: Permanent vascular access is an essential intervention in patients with advanced chronic kidney disease (CKD) and its success depends on various non-modifiable and modifiable factors. Considering the element of unpredictability and failure, we attempted to analyze various factors responsible for primary arteriovenous fistula (AVF) failure in presumed high-risk groups.Entities:
Keywords: Arteriovenous fistula; chronic kidney disease; factors; primary failure
Year: 2020 PMID: 33840957 PMCID: PMC8023032 DOI: 10.4103/ijn.IJN_214_19
Source DB: PubMed Journal: Indian J Nephrol ISSN: 0971-4065
Baseline characteristics detailed genderwise
| Variable | Male ( | Female ( | |
|---|---|---|---|
| Age (in years) | 48.22±18.62 | 45.43±17.82 | 0.3 |
| DM, | 52 (45.2) | 35 (42.6) | 0.38 |
| CGN, | 29 (25.2) | 14 (17.1) | 0.45 |
| CIN, | 33 (28.6) | 32 (39) | 0.39 |
| ADPKD, | 1 (0.9) | 1 (1.2) | 1 |
| Dialysis, | 49 (42.6) | 26 (31.7) | 0.1 |
| Hypertension (≥3 drugs) | 86 (74.7) | 34 (41.4) | 0.0001 |
| Hemoglobin (g/dL), mean±SD | 9.45±3.24 | 8.98±2.73 | 0.45 |
| S. creatinine (mg/dl), mean±SD | 5.42±3.34 | 5.73±3.02 | 0.01 |
| S. albumin (g/dl), mean±SD | 3.29±1.97 | 3.51±1.73 | 0.56 |
DM=Diabetes Mellitus, CGN=Chronic glomerulonephritis, CIN=Chronic tubulointerstitial nephritis, ADPKD=Autosomal dominant polycystic kidney disease, SD=Standard deviation
Figure 1Kaplan–Meier plot showing AVF survival over the duration of 24 weeks
Influence of gender with pre- and intraoperative variables on AVF success
| Variable ↓ | Functional AVF→ Subgroup↓ | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline ( | 24 h ( | 12 week ( | 24 week ( | Baseline ( | 24 h ( | 12 week ( | 24 week ( | ||
| Age | ≥65 years | 41 | 40 | 38 | 37 | 5 | 2 | 2 | 2 |
| Diabetes | Present | 52 | 48 | 47 | 46 | 35 | 30 | 29 | 28 |
| Hemodialysis | ≥ 2 weeks | 49 | 48 | 46 | 44 | 26 | 23 | 22 | 20 |
| Anastomosis | End-side | 66 | 59 | 58 | 56 | 42 | 37 | 36 | 35 |
| Side-side | 49 | 48 | 44 | 44 | 40 | 36 | 36 | 34 | |
| Type of AVF | RC | 102 | 97 | 93 | 93 | 45 | 37 | 36 | 33 |
| BC | 13 | 10 | 9 | 7 | 37 | 36 | 36 | 36 | |
| Arterial IMT | ≥0.26 mm | 75 | 70 | 69 | 67 | 29 | 24 | 23 | 22 |
| Arterial Plaque | Present | 53 | 48 | 43 | 43 | 23 | 18 | 18 | 16 |
| Loupe Magnification | Not Used | 29 | 27 | 27 | 27 | 19 | 13 | 13 | 13 |
| Thrill >60 min | Present | 108 | 107 | 102 | 100 | 72 | 73 | 72 | 69 |
| AVF Diameter | ≤5 mm | 26 | 20 | 16 | 14 | 28 | 19 | 18 | 15 |
AVF=Arteriovenous fistula, RC=Radiocephalic, BC=Brachiocephalic, IMT=Intima–media thickness
Influence of age with pre- and intraoperative variables on AVF success
| Variable ↓ | Functional AVF → Subgroup↓ | Age <65 years | Age ≥65 years | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline ( | 24 h ( | 12 week ( | 24 week ( | Baseline ( | 24 h ( | 12 week ( | 24 week ( | ||
| Gender | Male | 74 | 66 | 65 | 63 | 41 | 41 | 37 | 37 |
| Diabetes | Present | 70 | 64 | 64 | 61 | 17 | 15 | 13 | 13 |
| Nonfunctional AVF | Present | 20 | 18 | 17 | 15 | 16 | 16 | 16 | 16 |
| Hemodialysis | ≥2 weeks | 56 | 52 | 50 | 47 | 19 | 19 | 17 | 17 |
| Anastomosis | End-Side | 85 | 78 | 77 | 74 | 23 | 20 | 20 | 20 |
| Side-Side | 66 | 60 | 58 | 56 | 23 | 22 | 19 | 19 | |
| Type of AVF | RC | 128 | 119 | 117 | 112 | 19 | 17 | 14 | 14 |
| BC | 23 | 19 | 18 | 18 | 27 | 25 | 25 | 25 | |
| Arterial IMT | ≥0.26 mm | 75 | 65 | 64 | 64 | 29 | 25 | 25 | 25 |
| Arterial Plaque | Present | 41 | 38 | 36 | 33 | 34 | 32 | 31 | 31 |
| Loupe Magnification | Not Used | 35 | 32 | 32 | 30 | 13 | 10 | 10 | 10 |
| Thrill >60 min | Present | 142 | 138 | 135 | 130 | 38 | 39 | 39 | 39 |
| AVF Diameter | ≤5 mm | 37 | 26 | 24 | 19 | 17 | 14 | 10 | 10 |
AVF=Arteriovenous fistula, RC=Radiocephalic, BC=Brachiocephalic, IMT=Intima–media thickness
Influence of diabetes with pre and intraoperative variables on AVF success
| Variable ↓ | Functional AVF → Subgroup↓ | Diabetics | Nondiabetics | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline ( | 24 h ( | 12 week ( | 24 week ( | Baseline ( | 24 h ( | 12 week ( | 24 week ( | ||
| Gender | Female | 35 | 31 | 29 | 28 | 47 | 42 | 42 | 41 |
| Age | ≥ 65 years | 17 | 16 | 13 | 13 | 29 | 29 | 28 | 26 |
| Nonfunctional AVF | Present | 21 | 20 | 18 | 18 | 15 | 13 | 13 | 13 |
| Hemodialysis | ≥ 2 weeks | 32 | 28 | 27 | 26 | 43 | 41 | 40 | 38 |
| Anastomosis | End-Side | 44 | 39 | 37 | 37 | 64 | 57 | 56 | 56 |
| Side-Side | 43 | 41 | 40 | 37 | 46 | 43 | 41 | 39 | |
| Type of AVF | RC | 50 | 45 | 42 | 42 | 97 | 87 | 86 | 84 |
| BC | 37 | 35 | 35 | 32 | 13 | 14 | 11 | 11 | |
| Arterial IMT | ≥0.26 mm | 37 | 31 | 31 | 30 | 67 | 59 | 59 | 59 |
| Arterial Plaque | Present | 40 | 34 | 33 | 33 | 35 | 34 | 31 | 31 |
| Loupe Magnification | Not Used | 18 | 16 | 13 | 10 | 30 | 30 | 30 | 30 |
| Thrill >60 min | Present | 79 | 80 | 77 | 74 | 101 | 100 | 97 | 95 |
| AVF Diameter | ≤5 mm | 33 | 26 | 22 | 21 | 21 | 11 | 10 | 8 |
AVF=Arteriovenous fistula, IMT=Intima–media thickness
OR calculated in presumed high-risk categories with pre- and intraoperative variables
| Risk group | Variable | OR | 95% CI LL | 95% CI UL | |
|---|---|---|---|---|---|
| Females | Vs Males | 1.25 | 0.56 | 2.80 | 0.57 |
| Age ≥65 Years vs <65 Years | 10.05 | 1.49 | 67.77 | 0.018 | |
| Diabetes vs Nodiabetes | 1.71 | 0.52 | 5.62 | 0.38 | |
| HTN: ≥ 3 Drugs vs ≤2 Drugs | 1.81 | 0.55 | 5.98 | 0.33 | |
| Second AVF Creation vs First AVF | 6.6 | 1.17 | 37.34 | 0.031 | |
| Arterial Plaque Present | 3.86 | 1.13 | 13.16 | 0.028 | |
| Without Loupe Magnification | 3.6 | 1.06 | 12.83 | 0.03 | |
| Intraoperative Thrill Present | 345.0 | 28.59 | 4162.92 | <0.0001 | |
| Thrill at 24 h vs No Thrill | 345.0 | 28.59 | 4162.92 | <0.0001 | |
| Age ≥65 years | Males vs <65 Year | 0.62 | 0.18 | 2.08 | 0.43 |
| Females vs <65 Year | 10.05 | 1.49 | 67.77 | 0.018 | |
| Diabetes vs Nodiabetes | 2.66 | 0.51 | 13.72 | 0.24 | |
| HTN: ≥ 3 vs ≤2 Drugs | 3.46 | 0.18 | 67.52 | 0.41 | |
| Second AVF Creation vs First AVF | 0.09 | 0.01 | 1.78 | 0.11 | |
| Arterial Plaque Present | 0.19 | 0.03 | 1.04 | 0.06 | |
| Without Loupe Magnification | 2.17 | 0.41 | 11.44 | 0.36 | |
| Intraoperative Thrill Present | 342.33 | 12.54 | 9341.5 | 0.0005 | |
| Thrill at 24 h vs No thrill | 342.33 | 12.54 | 9341.5 | 0.0005 | |
| Diabetes | Males vs Nondiabetic Males | 1.04 | 0.37 | 2.92 | 0.93 |
| Females vs Nondiabetic Females | 1.71 | 0.52 | 5.62 | 0.38 | |
| Age≥65 Years vs <65 Years | 2.08 | 0.55 | 7.81 | 0.27 | |
| HTN: ≥ 3 Drugs vs ≤2 drugs | 0.19 | 0.03 | 0.97 | 0.04 | |
| Second AVF creation vs First AVF | 0.93 | 0.23 | 3.76 | 0.92 | |
| Arterial Plaque Present | 1.44 | 0.44 | 4.73 | 0.53 | |
| Without Loupe Magnification | 10.2 | 2.78 | 37.61 | 0.0005 | |
| Intraoperative Thrill Present | 103.6 | 10.5 | 1015.5 | 0.0001 | |
| Thrill at 24 h vs No Thrill | 103.6 | 10.5 | 1015.5 | 0.0001 |
OR=Odds ratio, CI=Confidence interval, LL=Lower limit, UL=Upper limit, vs=versus, HTN=Hypertension control, AVF=Arteriovenous fistula
RR in presumed high-risk categories with pre and intraoperative variables
| Risk Group | Variable | OR | 95% CI LL | 95% CI UL | |
|---|---|---|---|---|---|
| Females | RCAVF vs BCAVF | 9.86 | 1.34 | 72.46 | 0.02 |
| E-S vs S-S Anastomosis | 1.11 | 0.41 | 3.02 | 0.83 | |
| IMT: ≥ 0.26 mm vs ≤0.25 mm | 1.86 | 0.78 | 4.79 | 0.19 | |
| AVF Diameter: ≤5 mm vs ≥5.1 mm | 51.2 | 3.15 | 830.9 | 0.005 | |
| HD Duration: ≥2 Week vs <2 Week | 1.84 | 0.68 | 4.95 | 0.22 | |
| Age ≥65 years | RCAVF vs BCAVF | 3.55 | 0.77 | 16.42 | 0.09 |
| E-S vs S-S Anastomosis | 0.75 | 0.19 | 2.98 | 0.68 | |
| IMT: ≥ 0.26 mm vs≤0.25 mm | 0.78 | 0.19 | 3.08 | 0.72 | |
| AVF Diameter: ≤5 mm vs. ≥5.1 mm | 56.2 | 3.58 | 883.9 | 0.004 | |
| HD Duration: ≥2 Week vs <2 Week | 0.56 | 0.12 | 2.63 | 0.41 | |
| Diabetes | RCAVF vs BCAVF | 1.18 | 0.42 | 3.32 | 0.74 |
| E-S vs S-S Anastomosis | 1.14 | 0.42 | 3.11 | 0.79 | |
| IMT: ≥ 0.26 mm vs≤0.25 mm | 1.57 | 0.57 | 4.36 | 0.32 | |
| AVF Diameter: ≤5 mm vs. ≥5.1 mm | 19.36 | 2.67 | 144.8 | 0.002 | |
| HD Duration: ≥2 Week vs <2 Week | 2.43 | 0.74 | 7.98 | 0.14 |
RR=Relative risk, CI=Confidence interval, LL=Lower limit, UL=Upper limit, vs=versus, RCAVF=Radiocephalic arteriovenous fistula, BCAVF=Brachiocephalic arteriovenous fistula; E-S=End-to-side, S-S=Side-to-side, IMT=Intima–media thickness, AVF=Arteriovenous fistula, HD=Hemodialysis